Howard Colman
( out of 98 reviews )

Howard Colman, MD, PhD

Languages spoken: English

Clinical Locations

Primary Location

Huntsman Cancer Institute - Cancer Hospital South

Clinic 2B, Neuro-Oncology
1950 Circle of Hope
Salt Lake City , UT 84112
801-585-0250
Get Directions

Howard Colman, MD, PhD, has multiple clinical interests including the treatment of primary and metastatic brain tumors, and the diagnosis and management of neurologic complications of cancer. His clinical research is focused on the development and testing of new therapies for brain tumors. His laboratory interests include the identification of molecular markers of prognosis and treatment response in brain tumors and the role of tumors stem cells in the development and treatment resistance of brain tumors. He is a Jon M. Huntsman Presidential Professor in the Department of Neurosurgery, a member of the multidisciplinary Brain Tumor Research Team, and is Leader of the Center for Neurologic Cancers at Huntsman Cancer Institute (HCI) at the University of Utah. He is also an HCI investigator and a member of the Experimental Therapeutics program.

Specialties

Board Certification

American Board of Psychiatry & Neurology (Neurology)
United Council for Neurologic Subspecialties (Neuro-oncology)

Patient Rating

4.8 /5
( out of 98 reviews )

The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

The scale on which responses are measured is 1 to 5 with 5 being the best score.

Patient Comments

Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

HUNTSMAN CANCER CENTER

In addition to accomplishing the main purposes of our visit he diagnosed a problem I was having in my mouth that was causing me great difficulty and prescribed medicine for it.

HUNTSMAN CANCER CENTER

video visit - it was great.

HUNTSMAN CANCER CENTER

good explanations were given

HUNTSMAN CANCER CENTER

Dr. Colman has always explained things in a way both myself and my husband can comprehend. I've been thru several different cancer therapies and he explained the process, the possible outcomes and that's how things have been going.

HUNTSMAN CANCER CENTER

Dr Colman is amazing at explaining things to us and always lets us know our options. He is brilliant and his team is awesome too.

HUNTSMAN CANCER CENTER

Dr. Colman is great at explaining why and how my treatments are going.

HUNTSMAN CANCER CENTER

Dr. Colman is a wonderful neuro-oncologist! He listens to you about your concerns and reassures you that how things can work out. I would recommend him to be your neuro-oncologist.

HUNTSMAN CANCER CENTER

Dr. Colman listens to any concern I have and answers my questions to the best of his ability. I appreciate how concerned he is and providing options to me.

HUNTSMAN CANCER CENTER

I have a great deal of respect for Dr. Colman. He's always taken the time to make sure I understand what I'm seeing on my MRI scans and why my treatment is changing.

Howard Colman, MD, PhD, has multiple clinical interests including the treatment of primary and metastatic brain tumors, and the diagnosis and management of neurologic complications of cancer. His clinical research is focused on the development and testing of new therapies for brain tumors. His laboratory interests include the identification of molecular markers of prognosis and treatment response in brain tumors and the role of tumors stem cells in the development and treatment resistance of brain tumors. He is a Jon M. Huntsman Presidential Professor in the Department of Neurosurgery, a member of the multidisciplinary Brain Tumor Research Team, and is Leader of the Center for Neurologic Cancers at Huntsman Cancer Institute (HCI) at the University of Utah. He is also an HCI investigator and a member of the Experimental Therapeutics program.

Board Certification and Academic Information

Academic Departments Neurology -Adjunct Professor
Neurosurgery -Professor
Internal Medicine -Adjunct Professor
Academic Divisions Oncology
Board Certification
American Board of Psychiatry & Neurology (Neurology)
United Council for Neurologic Subspecialties (Neuro-oncology)

Education history

Undergraduate Neural Sciences - Brown University Sc.B.
Doctoral Training Neuroscience - Washington University School of Medicine Ph.D.
Professional Medical Medicine - Washington University School of Medicine M.D.
Internship Medicine - Barnes-Jewish Hospital, Washington University School of Medicine Intern
Residency Neurology - Barnes-Jewish Hospital, Washington University School of Medicine Resident
Chief Resident Neurology - Washington University School of Medicine Chief Resident
Fellowship Neuro-Oncology - University of Texas M.D. Anderson Cancer Center Fellow

Selected Publications

Journal Article

  1. Brat DJ, Aldape K, Colman H, Figrarella-Branger D, Fuller GN, Giannini C, Holland EC, Jenkins RB, Kleinschmidt-DeMasters B, Komori T, Kros JM, Louis DN, McLean C, Perry A, Reifenberger G, Sarkar C, Stupp R, van den Bent MJ, von Deimling A, Weller (2020). cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta neuropathologica, 139(3), 603-608.
  2. Cohen AL, Colman (2015). Glioma biology and molecular markers. Cancer treatment and research, 163, 15-30.
  3. Saito N, Fu J, Zheng S, Yao J, Wang S, Liu DD, Yuan Y, Sulman EP, Lang FF, Colman H, Verhaak RG, Yung WK, Koul (2014). A high Notch pathway activation predicts response to ¿ secretase inhibitors in proneural subtype of glioma tumor-initiating cells. Stem cells (Dayton, Ohio), 32(1), 301-12.
  4. Hossain A, Gumin J, Gao F, Figueroa J, Shinojima N, Takezaki T, Priebe W, Villarreal D, Kang SG, Joyce C, Sulman E, Wang Q, Marini FC, Andreeff M, Colman H, Lang F (2015). Mesenchymal Stem Cells Isolated From Human Gliomas Increase Proliferation and Maintain Stemness of Glioma Stem Cells Through the IL-6/gp130/STAT3 Pathway. Stem cells (Dayton, Ohio), 33(8), 2400-15.
  5. Ceccarelli M, et al. (TCGA Research Network, Colman H (2016). Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell, 146(3), 550-563.
  6. Wen PY, Touat M, Alexander BM, Mellinghoff IK, Ramkissoon S, McCluskey CS, Pelton K, Haidar S, Basu SS, Gaffey SC, Brown LE, Martinez-Ledesma JE, Wu S, Kim J, Wei W, Park MA, Huse JT, Kuhn JG, Rinne ML, Colman H, Agar NYR, Omuro AM, DeAngelis LM, Gilbert MR, de Groot JF, Cloughesy TF, Chi AS, Roberts TM, Zhao JJ, Lee EQ, Nayak L, Heath JR, Horky LL, Batchelor TT, Beroukhim R, Chang SM, Ligon AH, Dunn IF, Koul D, Young GS, Prados MD, Reardon DA, Yung WKA, Ligon K (2019). Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. Journal of clinical oncology, 37(9), 741-750.
  7. Ramaswamy V, Hielscher T, Mack SC, Lassaletta A, Lin T, Pajtler KW, Jones DT, Luu B, Cavalli FM, Aldape K, Remke M, Mynarek M, Rutkowski S, Gururangan S, McLendon RE, Lipp ES, Dunham C, Hukin J, Eisenstat DD, Fulton D, van Landeghem FK, Santi M, van Veelen MC, Van Meir EG, Osuka S, Fan X, Muraszko KM, Tirapelli DP, Oba-Shinjo SM, Marie SK, Carlotti CG, Lee JY, Nageswara Rao AA, Giannini C, Faria CC, Nunes S, Mora J, Hamilton RL, Hauser P, Jabado N, Petrecca K, Jung S, Massimi L, Zollo M, Cinalli G, Bognár L, Klekner A, Hortobágyi T, Leary S, Ermoian RP, Olson JM, Leonard JR, Gardner C, Grajkowska WA, Chambless LB, Cain J, Eberhart CG, Ahsan S, Massimino M, Giangaspero F, Buttarelli FR, Packer RJ, Emery L, Yong WH, Soto H, Liau LM, Everson R, Grossbach A, Shalaby T, Grotzer M, Karajannis MA, Zagzag D, Wheeler H, von Hoff K, Alonso MM, Tuñon T, Schüller U, Zitterbart K, Sterba J, Chan JA, Guzman M, Elbabaa SK, Colman H, Dhall G, Fisher PG, Fouladi M, Gajjar A, Goldman S, Hwang E, Kool M, Ladha H, Vera-Bolanos E, Wani K, Lieberman F, Mikkelsen T, Omuro AM, Pollack IF, Prados M, Robins HI, Soffietti R, Wu J, Metellus P, Tabori U, Bartels U, Bouffet E, Hawkins CE, Rutka JT, Dirks P, Pfister SM, Merchant TE, Gilbert MR, Armstrong TS, Korshunov A, Ellison DW, Taylor M (2016). Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis [Epub ahead of print]. Journal of clinical oncology, 34(21), 2468-2477.
  8. Cohen AL, Anker CJ, Johnson B, Burt LM, Shrieve DC, Salzman K, Jensen R, Boucher K, Colman (2020). Repeat radiation with bevacizumab and minocycline in bevacizumab-refractory high grade gliomas: a prospective phase 1 trial. Journal of neuro-oncology, 148(3), 577-585.
  9. Frandsen J, Orton A, Jensen R, Colman H, Cohen AL, Tward J, Shrieve DC, Suneja (2018). Patterns of care and outcomes in gliosarcoma: an analysis of the National Cancer Database. Journal of neurosurgery, 128(4), 1133-1138.
  10. Sathyan P, Zinn PO, Marisetty AL, Liu B, Kamal MM, Singh SK, Bady P, Lu L, Wani KM, Veo BL, Gumin J, Kassem DH, Robinson F, Weng C, Baladandayuthapani V, Suki D, Colman H, Bhat KP, Sulman EP, Aldape K, Colen RR, Verhaak RG, Lu Z, Fuller GN, Huang S, Lang FF, Sawaya R, Hegi M, Majumder (2015). Mir-21-Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact. The Journal of neuroscience, 35(45), 15097-112.
  11. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta M (2014). A randomized trial of bevacizumab for newly diagnosed glioblastoma. The New England journal of medicine, 370(8), 699-708.
  12. The Cancer Genome Atlas Network (2015). Comprehensive and Integrative Genomic Characterization of Diffuse Lower Grade Gliomas DOI: 10.1056/NEJMoa1402121 *Includes Colman, H. The New England journal of medicine, 372(26), 2481-2498.
  13. Lim-Fat MJ, Bi WL, Lo J, Lee EQ, Ahluwalia MS, Batchelor TT, Chang SM, Chiocca EA, Chukwueke U, Cloughesy TF, Colman H, Deangelis LM, Galanis E, Gilbert MR, De Groot JF, Lassman AB, Liau LM, Mason W, McFaline-Figueroa JR, Mehta MP, Mellinghoff IK, Nabors LB, Nayak L, Reardon DA, Wen P (2019). Letter: When Less is More: Dexamethasone Dosing for Brain Tumors. Neurosurgery, 85(3), E607-E608.
  14. Au TH, Willis C, Reblin M, Peters KB, Nghiemphu PL, Taylor JW, Colman H, Cohen AL, Ormond DR, Chakravarti A, Willmarth N, Menon J, Ma J, Bauer H, Watanabe AH, Ulrich CM, Singh P, Marshall A, Korytowsky B, Stenehjem D, Brixner (2021). Caregiver burden by treatment and clinical characteristics of patients with glioblastoma. Supportive care in cancer, 30(2), 1365-1375.
  15. Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM, Kawaguchi ES, Du L, Li G, Yong WH, Gaffey SC, Cohen AL, Mellinghoff IK, Lee EQ, Reardon DA, O'Brien BJ, Butowski NA, Nghiemphu PL, Clarke JL, Arrillaga-Romany IC, Colman H, Kaley TJ, de Groot JF, Liau LM, Wen PY, Prins R (2019). Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nature medicine, 25(3), 477-486.
  16. Nayak L, Molinaro AM, Peters K, Clarke JL, Jordan JT, de Groot J, Nghiemphu L, Kaley T, Colman H, McCluskey C, Gaffey S, Smith TR, Cote DJ, Severgnini M, Yearley JH, Zhao Q, Blumenschein WM, Duda DG, Muzikansky A, Jain RK, Wen PY, Reardon D (2021). Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. Clinical cancer research, 27(4), 1048-1057.
  17. Singh K, Batich KA, Wen PY, Tan AC, Bagley SJ, Lim M, Platten M, Colman H, Ashley DM, Chang SM, Rahman R, Galanis E, Mansouri A, Puduvalli VK, Reardon DA, Sahebjam S, Sampson JH, Simes J, Berry DA, Zadeh G, Cloughesy TF, Mehta MP, Piantadosi S, Weller M, Heimberger AB, Khasraw (2021). Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. Clinical cancer research, 28, 585-593.
  18. Penas-Prado M, Hess KR, Fisch MJ, Lagrone LW, Groves MD, Levin VA, De Groot JF, Puduvalli VK, Colman H, Volas-Redd G, Giglio P, Conrad CA, Salacz ME, Floyd JD, Loghin ME, Hsu SH, Gonzalez J, Chang EL, Woo SY, Mahajan A, Aldape KD, Yung WK, Gilbert MR, MD Anderson Community Clinical Oncology Program., Brain Tumor Trials Collaborative (2015). Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. Neuro-oncology, 17(2), 266-73.
  19. Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, Cloughesy TF, Marimuthu A, Haidar S, Perry A, Huse J, Phillips J, West BL, Nolop KB, Hsu HH, Ligon KL, Molinaro AM, Prados (2016). Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro-oncology, 18(4), 557-64.
  20. Colman (2017). Toward more informative biomarker-based clinical trials in glioblastoma. Neuro-oncology, 19(7), 880-881.
  21. Vera-Bolanos E, Aldape K, Yuan Y, Wu J, Wani K, Necesito-Reyes MJ, Colman H, Dhall G, Lieberman FS, Metellus P, Mikkelsen T, Omuro A, Partap S, Prados M, Robins HI, Soffietti R, Wu J, Gilbert MR, Armstrong TS, CERN Foundation (2015). Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. Neuro-oncology, 17(3), 440-7.
  22. Puduvalli VK, Wu J, Yuan Y, Armstrong TS, Vera E, Wu J, Xu J, Giglio P, Colman H, Walbert T, Raizer J, Groves MD, Tran D, Iwamoto F, Avgeropoulos N, Paleologos N, Fink K, Peereboom D, Chamberlain M, Merrell R, Penas Prado M, Yung WKA, Gilbert M (2020). A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma. Neuro-oncology, 22(10), 1505-1515.
  23. Ellingson BM, Brown MS, Boxerman JL, Gerstner ER, Kaufmann TJ, Cole PE, Bacha JA, Leung D, Barone A, Colman H, van den Bent MJ, Wen PY, Alfred Yung WK, Cloughesy TF, Goldin J (2021). Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trials. Neuro-oncology, 23(2), 189-198.
  24. Prados MD, Byron SA, Tran NL, Phillips JJ, Molinaro AM, Ligon KL, Wen PY, Kuhn JG, Mellinghoff IK, de Groot JF, Colman H, Cloughesy TF, Chang SM, Ryken TC, Tembe WD, Kiefer JA, Berens ME, Craig DW, Carpten JD, Trent J (2015). Toward precision medicine in glioblastoma: the promise and the challenges. Neuro-oncology, 17(8), 1051-63.
  25. Hummel S, Kohlmann W, Kollmeyer TM, Jenkins R, Sonnen J, Palmer CA, Colman H, Abbott D, Cannon-Albright L, Cohen A (2019). The contribution of the rs55705857 G allele to familial cancer risk as estimated in the Utah population database. BMC cancer, 19(1), 190.
  26. Chen R, Ravindra VM, Cohen AL, Jensen RL, Salzman KL, Prescot AP, Colman (2015). Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas. Neurosurgical focus, 38(3), E2.
  27. Karsy M, Neil JA, Guan J, Mahan MA, Colman H, Jensen R (2015). A practical review of prognostic correlations of molecular biomarkers in glioblastoma. Neurosurgical focus, 38(3), E4.
  28. Bhat KPL, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F, Wani K, Heathcock L, James JD, Goodman LD, Conroy S, Long L, Lelic N, Wang S, Gumin J, Raj D, Kodama Y, Raghunathan A, Olar A, Joshi K, Pelloski CE, Heimberger A, Kim SH, Cahill DP, Rao G, Den Dunnen WFA, Boddeke HWGM, Phillips HS, Nakano I, Lang FF, Colman H, Sulman EP, Aldape (2013). Mesenchymal differentiation mediated by NF-¿B promotes radiation resistance in glioblastoma. Cancer cell, 24(3), 331-46.
  29. Werner CK, Nna UJ, Sun H, Wilder-Romans K, Dresser J, Kothari AU, Zhou W, Yao Y, Rao A, Stallard S, Koschmann C, Bor T, Debinski W, Hegedus AM, Morgan MA, Venneti S, Baskin-Bey E, Spratt DE, Colman H, Sarkaria JN, Chinnaiyan AM, Eisner JR, Speers C, Lawrence TS, Strowd RE, Wahl D (2020). Expression of the Androgen Receptor Governs Radiation Resistance in a Subset of Glioblastomas Vulnerable to Antiandrogen Therapy. Molecular cancer therapeutics, 19(10), 2163-2174.
  30. Choi H, Gillespie DL, Berg S, Rice C, Couldwell S, Gu J, Colman H, Jensen RL, Huang L (2015). Intermittent induction of HIF-1¿ produces lasting effects on malignant progression independent of its continued expression. PloS one, 10(4), e0125125.
  31. Kumthekar P, Ko CH, Paunesku T, Dixit K, Sonabend AM, Bloch O, Tate M, Schwartz M, Zuckerman L, Lezon R, Lukas RV, Jovanovic B, McCortney K, Colman H, Chen S, Lai B, Antipova O, Deng J, Li L, Tommasini-Ghelfi S, Hurley LA, Unruh D, Sharma NV, Kandpal M, Kouri FM, Davuluri RV, Brat DJ, Muzzio M, Glass M, Vijayakumar V, Heidel J, Giles FJ, Adams AK, James CD, Woloschak GE, Horbinski C, Stegh A (2021). A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma. Science translational medicine, 13(584),
  32. Karsy M, Guan J, Jensen R, Huang LE, Colman (2016). The Impact of Hypoxia and Mesenchymal Transition on Glioblastoma Pathogenesis and Cancer Stem Cells Regulation. World neurosurgery, 88, 222-236.
  33. Yuan S, Lu Y, Yang J, Chen G, Kim S, Feng L, Ogasawara M, Hammoudi N, Lu W, Zhang H, Liu J, Colman H, Lee JS, Li XN, Xu RH, Huang P, Wang (2015). Metabolic activation of mitochondria in glioma stem cells promotes cancer development through a reactive oxygen species-mediated mechanism. Stem cell research & therapy, 6(1), 198.
  34. Balasubramaniyan V, Vaillant B, Wang S, Gumin J, Butalid ME, Sai K, Mukheef F, Kim SH, Boddeke HW, Lang F, Aldape K, Sulman EP, Bhat KP, Colman (2015). Aberrant mesenchymal differentiation of glioma stem-like cells: implications for therapeutic targeting. Oncotarget, 6(31), 31007-17.
  35. Philip B, Yu DX, Silvis MR, Shin CH, Robinson JP, Robinson GL, Welker AE, Angel SN, Tripp SR, Sonnen JA, VanBrocklin MW, Gibbons RJ, Looper RE, Colman H, Holmen S (2018). Mutant IDH1 Promotes Glioma Formation In Vivo. Cell reports, 23(5), 1553-1564.
  36. Wang Y, Xu X, Maglic D, Dill MT, Mojumdar K, Ng PK, Jeong KJ, Tsang YH, Moreno D, Bhavana VH, Peng X, Ge Z, Chen H, Li J, Chen Z, Zhang H, Han L, Du D, Creighton CJ, Mills GB, Cancer Genome Atlas Research Network, Camargo F, Liang (2018). Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer. Cell reports, 25(5), 1304-1317.e5.
  37. Holowatyj AN, Viskochil R, Ose D, Tingey B, Haaland B, Wilson D, Larson M, Feltz S, Lewis MA, Colman H, Ulrich C (2021). Diabetes, Body Fatness, and Insulin Prescription Among Adolescents and Young Adults with Cancer. Journal of adolescent and young adult oncology, 10(2), 217-225.
  38. Colman (2020). Adult Gliomas. Continuum (Minneapolis, Minn.), 26(6), 1452-1475.
  39. Ippen FM, Colman H, van den Bent MJ, Brastianos P (2018). Precision Medicine for Primary Central Nervous System Tumors: Are We There Yet?. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 38(38), 158-167.
  40. Smith-Cohn M, Davidson C, Colman H, Cohen A (2019). Challenges of targeting BRAF V600E mutations in adult primary brain tumor patients: a report of two cases. CNS oncology, 8(4), CNS48.
  41. Cohen A, Sato M, Aldape K, Mason CC, Alfaro-Munoz K, Heathcock L, South ST, Abegglen LM, Schiffman JD, Colman (2015). DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status. Acta neuropathologica communications, 3, 34.
  42. Tan AC, Bagley SJ, Wen PY, Lim M, Platten M, Colman H, Ashley DM, Wick W, Chang SM, Galanis E, Mansouri A, Khagi S, Mehta MP, Heimberger AB, Puduvalli VK, Reardon DA, Sahebjam S, Simes J, Antonia SJ, Berry D, Khasraw (2021). Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. Journal for immunotherapy of cancer, 9(7),
  43. Wang X, Haaland B, Hu-Lieskovan S, Colman H, Holmen S (2021). First line immunotherapy extends brain metastasis free survival, improves overall survival, and reduces the incidence of brain metastasis in patients with advanced melanoma. Cancer reports (Hoboken, N.J.), 4(6), e1419.
  44. Griguer CE, Oliva CR, Coffey CS, Cudkowicz ME, Conwit RA, Gudjonsdottir AL, Ecklund DJ, Fedler JK, Neill-Hudson TM, Nabors LB, Benge M, Hackney JR, Chase M, Leonard TP, Patel T, Colman H, de la Fuente M, Chaudhary R, Marder K, Kreisl T, Mohile N, Chheda MG, McNeill K, Kumthekar P, Dogan A, Drappatz J, Puduvalli V, Kowalska A, Graber J, Gerstner E, Clark S, Salacz M, Markert (2021). Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial. Neuro-oncology advances, 4(1), 1-10.
  45. Brat DJ, Aldape K, Bridge JA, Canoll P, Colman H, Hameed MR, Harris BT, Hattab EM, Huse JT, Jenkins RB, Lopez-Terrada DH, McDonald WC, Rodriguez FJ, Souter LH, Colasacco C, Thomas NE, Yount MH, van den Bent MJ, Perry (2022). Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas. Archives of pathology & laboratory medicine, 146(5), 547-574.
  46. Ellingson BM, Gerstner ER, Lassman AB, Chung C, Colman H, Cole PE, Leung D, Allen JE, Ahluwalia MS, Boxerman J, Brown M, Goldin J, Nduom E, Hassan I, Gilbert MR, Mellinghoff IK, Weller M, Chang S, Arons D, Meehan C, Selig W, Tanner K, Yung WKA, van den Bent M, Wen PY, Cloughesy T (2022). Hypothetical Generalized Framework for a New Imaging Endpoint of Therapeutic Activity in Early Phase Clinical Trials in Brain Tumors. Neuro-oncology, 24, 1219-1229.
  47. Peoples AR, Oswald LB, Ose J, Daniels B, Himbert C, Hathaway CA, Gigic B, Kirchhoff AC, Lin T, Grossman D, Tward J, Varghese TK Jr, Figueiredo JC, Toriola AT, Beck A, Scaife C, Shibata D, LaStayo P, Gonzalez B, Salas K, Ashworth A, Matsen C, Christenson C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Schneider M, Penedo FJ, Siegel EM, Tworoger SS, Ulrich C (2022). Impact of the COVID-19 pandemic on rural and urban cancer patients' experiences, health behaviors, and perceptions. The Journal of rural health, 38(4), 886-899.
  48. de la Fuente MI, Colman H, Rosenthal M, Van Tine BA, Levacic D, Walbert T, Gan HK, Vieito M, Milhem MM, Lipford K, Forsyth S, Guichard SM, Mikhailov Y, Sedkov A, Brevard J, Kelly PF, Mohamed H, Monga (2022). Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: a multicenter, open-label, phase 1b/2 trial. Neuro-oncology, 25, 146-156.
  49. Himbert C, Hathaway CA, Daniels B, Salas K, Ashworth A, Gigic B, Lin T, Viskochil R, Kirchhoff AC, Grossman D, Ose J, Tward J, Scaife C, Figueiredo JC, Toriola AT, Beck A, Shibata D, Gonzalez BD, Matsen C, Christenson C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Schneider M, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM, Peoples A (2022). Factors associated with changes in exercise behaviors during the COVID-19 pandemic. Cancer causes & control, 33(7), 939-950.
  50. Gelhard S, Maxwell A, Colman H, Cohen AL, Mendez J (2022). Consolidation regimens in primary central nervous system lymphoma: a single-center retrospective cohort evaluating survival outcomes and cost-benefit analysis. Journal of neuro-oncology, 159(2), 293-300.
  51. Wu Z, Rajan S, Chung HJ, Raffeld M, Panneer Selvam P, Schweizer L, Perry A, Samuel D, Giannini C, Ragunathan A, Frosch MP, Marshall MS, Boué DR, Donev K, Neill SG, Fernandes I, Resnick A, Rood B, Cummings TJ, Buckley AF, Szymanski L, Neto OLA, Zach L, Colman H, Cheshier S, Ziskin J, Tyagi M, Capper D, Abdullaev Z, Cimino PJ, Quezado M, Pratt D, Aldape (2022). Molecular and clinicopathologic characteristics of gliomas with EP300::BCOR fusions. Acta neuropathologica, 144(6), 1175-1178.
  52. Cimino PJ, Ketchum C, Turakulov R, Singh O, Abdullaev Z, Giannini C, Pytel P, Lopez GY, Colman H, Nasrallah MP, Santi M, Fernandes IL, Nirschl J, Dahiya S, Neill S, Solomon D, Perez E, Capper D, Mani H, Caccamo D, Ball M, Badruddoja M, Chkheidze R, Camelo-Piragua S, Fullmer J, Alexandrescu S, Yeaney G, Eberhart C, Martinez-Lage M, Chen J, Zach L, Kleinschmidt-DeMasters BK, Hefti M, Lopes MB, Nuechterlein N, Horbinski C, Rodriguez FJ, Quezado M, Pratt D, Aldape (2022). Expanded analysis of high-grade astrocytoma with piloid features identifies an epigenetically and clinically distinct subtype associated with neurofibromatosis type 1. Acta neuropathologica, 145, 71-82.
  53. Morris BB, Smith JP, Zhang Q, Jiang Z, Hampton OA, Churchman ML, Arnold SM, Owen DH, Gray JE, Dillon PM, Soliman HH, Stover DG, Colman H, Chakravarti A, Shain KH, Silva AS, Villano JL, Vogelbaum MA, Borges VF, Akerley WL, Gentzler RD, Hall RD, Matsen CB, Ulrich CM, Post AR, Nix DA, Singer EA, Larner JM, Stukenberg PT, Jones DR, Mayo M (2022). Replicative Instability Drives Cancer Progression. Biomolecules, 12(11),
  54. Au TH, Willis C, Reblin M, Peters KB, Nghiemphu PL, Taylor JW, Colman H, Cohen AL, Ormond DR, Neil EC, Chakravarti A, Willmarth N, Balajonda BC, Menon J, Ma J, Bauer H, Nelson RS, Tan MS, Singh P, Marshall A, Korytowsky B, Stenehjem D, Brixner (2023). Caregiver survey in glioblastoma focused on cognitive dysfunction: development and results from a multicenter study. Future oncology (London, England), 19(2), 173-188.
  55. Nassiri F, Patil V, Yefet LS, Singh O, Liu J, Dang RMA, Yamaguchi TN, Daras M, Cloughesy TF, Colman H, Kumthekar PU, Chen CC, Aiken R, Groves MD, Ong SS, Ramakrishna R, Vogelbaum MA, Khagi S, Kaley T, Melear JM, Peereboom DM, Rodriguez A, Yankelevich M, Nair SG, Puduvalli VK, Aldape K, Gao A, López-Janeiro Á, de Andrea CE, Alonso MM, Boutros P, Robbins J, Mason WP, Sonabend AM, Stupp R, Fueyo J, Gomez-Manzano C, Lang FF, Zadeh (2023). Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. Nature medicine, 29(6), 1370-1378.
  56. Singh K, Hotchkiss KM, Parney IF, De Groot J, Sahebjam S, Sanai N, Platten M, Galanis E, Lim M, Wen PY, Minniti G, Colman H, Cloughesy TF, Mehta MP, Geurts M, Arrillaga-Romany I, Desjardins A, Tanner K, Short S, Arons D, Duke E, Wick W, Bagley SJ, Ashley DM, Kumthekar P, Verhaak R, Chalmers AJ, Patel AP, Watts C, Fecci PE, Batchelor TT, Weller M, Vogelbaum MA, Preusser M, Berger MS, Khasraw (2023). Correcting the drug development paradigm for glioblastoma requires serial tissue sampling. Nature medicine, 29(10), 2402-2405.
  57. Earl ER, Colman H, Mendez J, Jensen RL, Karsy (2023). An evaluation of biobanking and therapeutic clinical trial representation among adult glioma patients from rural and urban Utah. Neuro-oncology practice, 10(5), 472-481.
  58. Rahman R, Trippa L, Lee EQ, Arrillaga-Romany I, Fell G, Touat M, McCluskey C, Wiley J, Gaffey S, Drappatz J, Welch MR, Galanis E, Ahluwalia MS, Colman H, Nabors LB, Hepel J, Elinzano H, Schiff D, Chukwueke UN, Beroukhim R, Nayak L, McFaline-Figueroa JR, Batchelor TT, Rinne ML, Kaley TJ, Lu-Emerson C, Mellinghoff IK, Bi WL, Arnaout O, Peruzzi PP, Haas-Kogan D, Tanguturi S, Cagney D, Aizer A, Doherty L, Lavallee M, Fisher-Longden B, Dowling S, Geduldig J, Watkinson F, Pisano W, Malinowski S, Ramkissoon S, Santagata S, Meredith DM, Chiocca EA, Reardon DA, Alexander BM, Ligon KL, Wen P (2023). Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization. Journal of clinical oncology, 41(36), 5524-5535.
  59. Eljilany I, Saghand PG, Chen J, Ratan A, McCarter M, Carpten J, Colman H, Ikeguchi AP, Puzanov I, Arnold S, Churchman M, Hwu P, Conejo-Garcia J, Dalton WS, Weiner GJ, El Naqa IM, Tarhini A (2023). The T Cell Immunoscore as a Reference for Biomarker Development Utilizing Real-World Data from Patients with Advanced Malignancies Treated with Immune Checkpoint Inhibitors. Cancers, 15(20), 4913.
  60. Aßmann E, Ose J, Hathaway CA, Oswald LB, Hardikar S, Himbert C, Chellam V, Lin T, Daniels B, Kirchhoff AC, Gigic B, Grossman D,Tward J, Varghese TK Jr, Shibata D, Figueiredo JC, Toriola AT, Beck A, Scaife C, Branes CA, Matsen C, Ma DS, Colman H, Hunt JP,Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Grady WM, Schneider M, Dinkel A, Islam JY, Gonzalez BD, Ott o AK,Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM, Peoples AR (2024). Risk factors and health behaviors associated with loneliness among cancer survivors during the COVID-19 pandemic . Journal of Behavioral Medicine, 47(3), 405-421.
  61. Underhill HR, Karsy M, Davidson CJ, Hellwig S, Stevenson S, Goold EA, Vincenti S, Sellers DL, Dean C, Harrison BE, Bronner MP, Colman H, Jensen R (2024). Subclonal Cancer Driver Mutations are Prevalent in the Unresected Peritumoral Edema of Adult Diffuse Gliomas. Cancer research, 84(7), 1149-1164.
  62. Arnold LM, Hoshina Y, Lee H, Colman H, Mendez (2024). Effect of Pneumocystis jirovecii pneumonia prophylaxis on hematologic toxicity in patients receiving chemoradiation for primary brain tumors. Journal of neuro-oncology, 167(1), 211-217.
  63. Demetriou AN, Chow F, Craig DW, Webb MG, Ormond DR, Battiste J, Chakravarti A, Colman H, Villano JL, Schneider BP, Liu JKC, Churchman ML, Zada (2024). Profiling the molecular and clinical landscape of glioblastoma utilizing the Oncology Research Information Exchange Network brain cancer database. Neuro-oncology advances, 6(1), vdae046.
  64. McKean WB, Yang J, Boucher K, Shrieve DC, Suneja G, Salzman K, Jensen R, Cohen AL*, Colman H* (*Equal Contribution (2024). D-TERMINED, a phase 1 trial in newly diagnosed high-grade glioma with temozolomide, radiation, and minocycline followed by adjuvant minocycline/temozolomide. Neuro-oncology advances, 6(1), vdae063.
  65. Ose DJ, Adediran E, Mark B, Ocier K, Dunson WA Jr, Turner C, Taylor B, Svoboda K, Post AR, Leiser J, Colman H, Ulrich CM, Hashibe (2024). The association of diabetes mellitus and routinely collected patient-reported outcomes in patients with cancer. A real-world cohort study. Cancer medicine, 13(20), e70246.
  66. Wang X, Li T, Eljilany I, Sukrithan V, Ratan A, McCarter M, Carpten J, Colman H, Ikeguchi AP, Puzanov I, Arnold S, Churchman M, Hwu P, Rodriguez PC, Dalton WS, Weiner GJ, Tarhini A (2024). Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitors. medRxiv, Preprint,
  67. Conway K, Edmiston SN, Vondras A, Reiner A, Corcoran DL, Shen R, Parrish EA, Hao H, Lin L, Kenney JM, Ilelaboye G, Kostrzewa CE, Kuan PF, Busam KJ, Lezcano C, Lee TK, Hernando E, Googe PB, Ollila DW, Moschos S, Gorlov I, Amos CI, Ernstoff MS, Cust AE, Wilmott JS, Scolyer RA, Mann GJ, Vergara IA, Ko J, Rees JR, Yan S, Nagore E, Bosenberg M, Rothberg BG, Osman I, Lee JE, Saenger Y, Bogner P, Thompson CL, Gerstenblith M, Holmen SL, Funchain P, Brunsgaard E, Depcik-Smith ND, Luo L, Boyce T, Orlow I, Begg CB, Berwick M, Thomas NE; InterMEL Study Grou (2024). DNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic Significance. JCO precision oncology, 8, e2400375.
  68. Eljilany I, Coleman S, Tan AC, McCarter MD, Carpten J, Colman H, Naqash AR, Puzanov I, Arnold SM, Churchman ML, Spakowicz D, Salhia B, Marin J, Ganesan S, Ratan A, Shriver C, Hwu P, Dalton WS, Weiner GJ, Conejo-Garcia JR, Rodriguez P, Tarhini A (2024). Differential Infiltration of Key Immune T-Cell Populations Across Malignancies Varying by Immunogenic Potential and the Likelihood of Response to Immunotherapy. Cells, 13(23), 1993.
  69. Mendez JS, Cohen AL, Eckenstein M, Jensen RL, Burt LM, Salzman KL, Chamberlain M, Hsu HH, Hutchinson M, Iwamoto F, Ligon KL, Mrugala MM, Pelayo M, Plotkin SR, Puduvalli VK, Raizer J, Reardon DA, Sterba M, Walbert T, West BL, Wong ET, Zhang C, Colman (2024). Phase 1b/2 study of orally administered pexidartinib in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma. Neuro-oncology advances, 6(1), vdae202.
  70. Seong CS, Huang C, Boese AC, Hou Y, Koo J, Mouw JK, Rupji M, Joseph G, Johnston HR, Claussen H, Switchenko JM, Behera M, Churchman M, Kolesar JM, Arnold SM, Kerrigan K, Akerley W, Colman H, Johns MA, Arciero C, Zhou W, Marcus AI, Ramalingam SS, Fu H, Gilbert-Ross (2023). Loss of the endocytic tumor suppressor HD-PTP phenocopies LKB1 and promotes RAS-driven oncogenesis. bioRxiv,
  71. Tarhini AA, Hedges D, Tan AC, Rodriguez P, Sukrithan V, Ratan A, McCarter MD, Carpten J, Colman H, Ikeguchi AP, Puzanov I, Arnold SM, Churchman ML, Hwu P, Conejo-Garcia JR, Dalton WS, Weiner GJ, Eljilany (2024). Differences in Co-Expression of T Cell Co-Inhibitory and Co-Stimulatory Molecules with PD-1 Across Different Human Cancers. Journal of oncology research and therapy, 9(2),
  72. Piotrowski AF, Shih K, Giglio P, Colman H, Wen PY, Campian JL, Butowski N, Cloughesy T, Zhu Z, Gisin V, Badruddoja (2025). Phase Ib/II Study of Pamiparib Plus Radiation Therapy and/or Temozolomide in Adult Patients with Treatment-Naïve or Recurrent/Refractory Glioblastoma. Current oncology (Toronto, Ont.), 32(10), 541.
  73. Colman H, Lombardi G, Wong ET, Walbert T, Eoli M, Lassman AB, Peereboom DM, Kizilbash SH, Kamiya-Matsuoka C, Pitz MW, Strowd RE, Desjardins A, Kumthekar P, Mason W, Pellerino A, Soffietti R, Butowski N, Forsyth PA, Hamza MA, Hau P, Lallana E, Nabors B, Piccioni D, Uhlmann EJ, Welsh LC, Wen PY, Dietrich J, Wang C, Levin V (2026). STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma. Journal of clinical oncology, 44(8), 641-652.
  74. Winn M, Pauleck S, Richardson S, Viskochil R, Karra P, Colman H, Doherty JA, Xu Y, Hu-Lieskovan S, Litchman M, Playdon MC, Hardikar (2025). New-onset prediabetes/diabetes worsens overall survival in patients with cancer: A real-world retrospective cohort study. Diabetes, obesity & metabolism, 2025(2), 1-11.
  75. Wang X, Li T, Eljilany I, Soupir A, Radmacher M, Agius P, Sukrithan V, Ratan A, McCarter M, Salhia B, Colman H, Naqash AR, Puzanov I, Arnold S, Marin-Acevedo JA, Ganesan S, Churchman M, Hwu P, Rodriguez PC, Dalton WS, Weiner GJ, Tarhini A (2025). Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitors. Nature communications, 16(1), 9968.
  76. Jhandi S, Jhandi AS, Cannon DM, Burt LM, DeCesaris C, Menacho ST, Colman H, Jensen R (2025). Stereotactic radiosurgery for radiation'induced meningiomas: long'term institutional outcomes with patient- and lesion'level analyses and an updated meta'analysis. Journal of neuro-oncology, 176(1), 122.
  77. Jones RL, Groisberg R, Blay JY, Colman H, De La Fuente M, Roxburgh P, Chao MM, Tian H, Duffaud F, Bahleda R, Van Tine B (2026). Olutasidenib in recurrent/relapsed locally advanced or metastatic IDH1-mutated chondrosarcoma: phase 1b/2 trial. Nature communications, 17(1), 2224.

Review

  1. Karsy M, Guan J, Cohen A, Colman H, Jensen R (2016). Medical Management of Meningiomas: Current Status, Failed Treatments, and Promising Horizons. Neurosurgery clinics of North America, 27(2), 249-60.
  2. Chen R, Cohen AL, Colman (2016). Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future. Current treatment options in oncology, 17(8), 42.

Case Report

  1. Sivakumar W, Oh N, Cutler A, Colman H, Couldwell W (2015). Cranial and spinal leptomeningeal dissemination in esthesioneuroblastoma: Two reports of distant central nervous system metastasis and rationale for treatment. Surgical neurology international, 6(Suppl 25), S628-32.

Editorial

  1. Colman (2019). A platform for efficient early evaluation of biomarker-associated therapies in newly diagnosed IDH wild-type, MGMT unmethylated glioblastoma. 21(1), 6-7.

Abstract

  1. deHoll S, Fritz K, Malani R, Colman H, Mendez J (2025). QLTI-08. Single institution experience with romiplostim for chemotherapy-induced thrombocytopenia in Gliomas . 27(Supplement_5), v375.
  2. Whipple N, Molinaro A, Reddy A, Jaeger-Krause M, Iv M, Villanueva-Meyer J, Lupo J, Cooney T, Raber S, Hoffman C, Jensen J, Prados M, Gartrell R, Kline C, Cheshier S, Mueller S, Colman (2025). CTP-18. PNOC025: A phase 1 study assessing the safety and tolerability of magrolimab in children and adults with recurrent or progressive malignant brain tumors . 27(Supplement_5), v149¿v150.

Other

  1. Himbert C, Hathaway CA, Daniels B, Salas K, Ashworth A, Gigic B, Lin T, Viskochil R, Kirchhoff AC, Grossman D, Ose J, Tward J, Scaife C, Figueiredo JC, Toriola AT, Beck A, Shibata D, Gonzalez BD, Matsen C, Christenson C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Schneider M, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM, Peoples A (2021). Impact of the COVID-19 pandemic on exercise habits among cancer patients. Research square,
  2. Au TH, Willis C, Reblin M, Peters KB, Nghiemphu PL, Taylor JW, Colman H, Cohen AL, Ormond DR, Chakravarti A, Willmarth N, Menon J, Ma J, Bauer H, Watanabe AH, Ulrich CM, Singh P, Marshall A, Korytowsky B, Stenehjem D, Brixner (2022). Correction to: Caregiver burden by treatment and clinical characteristics of patients with glioblastoma. Supportive care in cancer, 30(2), 1377-1378.
  3. Nassiri F, Patil V, Yefet LS, Singh O, Liu J, Dang RMA, Yamaguchi TN, Daras M, Cloughesy TF, Colman H, Kumthekar PU, Chen CC, Aiken R, Groves MD, Ong SS, Ramakrishna R, Vogelbaum MA, Khagi S, Kaley T, Melear JM, Peereboom DM, Rodriguez A, Yankelevich M, Nair SG, Puduvalli VK, Aldape K, Gao A, López-Janeiro Á, de Andrea CE, Alonso MM, Boutros P, Robbins J, Mason WP, Sonabend AM, Stupp R, Fueyo J, Gomez-Manzano C, Lang FF, Zadeh (2025). Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. Nature medicine, 31, 3204.

News & Podcasts

Huntsman Cancer Institute News